MCP server is live

Claude DesktopClaude Code (CLI)ChatGPTCursorVS Code

InSilico Medicine Cayman Valuation Multiples

Discover InSilico Medicine Cayman's revenue and EBITDA valuation multiples and investment history.

Start Free TrialSee companies similar to InSilico Medicine Cayman

InSilico Medicine Cayman Overview

About InSilico Medicine Cayman

InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from Hong Kong.

Founded

2018

HQ

Hong Kong

Employees

319

Financials (FY)

Revenue: $56M
EBITDA: ($347M)

EV

$3.1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

InSilico Medicine Cayman Financials

InSilico Medicine Cayman reported last fiscal year revenue of $56M and negative EBITDA of ($347M).

In the same fiscal year, InSilico Medicine Cayman generated $46M in gross profit, ($347M) in EBITDA losses, and had net loss of ($352M).

InSilico Medicine Cayman P&L

In the most recent fiscal year, InSilico Medicine Cayman reported revenue of $56M and EBITDA of ($347M).

InSilico Medicine Cayman is unprofitable as of last fiscal year, with gross margin of 82%, EBITDA margin of (617%), and net margin of (626%).

See analyst estimates for InSilico Medicine Cayman
Last FY202320242025202620272028
Revenue$56M$51M$86M$56M
Gross Profit$46M$39M$78M$46M
Gross Margin82%75%90%82%
EBITDA($347M)($207M)($11M)($347M)
EBITDA Margin(617%)(404%)(13%)(617%)
EBIT Margin(110%)(176%)(39%)(110%)
Net Profit($352M)($212M)($17M)($352M)
Net Margin(626%)(414%)(20%)(626%)

Financial data powered by Morningstar, Inc.

InSilico Medicine Cayman Stock Performance

InSilico Medicine Cayman has current market cap of $3.6B, and enterprise value of $3.1B.

Market Cap Evolution

InSilico Medicine Cayman's stock price is $6.18.

InSilico Medicine Cayman has an EPS (earnings per share) of $-0.61.

See more trading valuation data for InSilico Medicine Cayman
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3.1B$3.6B6.6%---$-0.61

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

InSilico Medicine Cayman Valuation Multiples

InSilico Medicine Cayman trades at 55.8x EV/Revenue multiple, and (9.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for InSilico Medicine Cayman

InSilico Medicine Cayman Financial Valuation Multiples

As of July 24, 2026, InSilico Medicine Cayman has market cap of $3.6B and EV of $3.1B.

InSilico Medicine Cayman has a P/E ratio of (10.2x).

Last FY202320242025202620272028
EV/Revenue55.8x61.3x36.5x55.8x
EV/EBITDA(9.0x)(15.1x)n/m(9.0x)
EV/EBIT(50.5x)(34.9x)(93.9x)(50.5x)
EV/Gross Profit68.4x81.3x40.4x68.4x
P/E(10.2x)(16.9x)(209.2x)(10.2x)
EV/FCF(39.3x)(96.3x)(53.8x)(39.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified InSilico Medicine Cayman Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

InSilico Medicine Cayman Margins & Growth Rates

In the most recent fiscal year, InSilico Medicine Cayman reported gross margin of 82%, EBITDA margin of (617%), and net margin of (626%).

See estimated margins and future growth rates for InSilico Medicine Cayman

InSilico Medicine Cayman Margins

Last FY20242025202720282029
Gross Margin82%90%82%
EBITDA Margin(617%)(13%)(617%)
EBIT Margin(110%)(39%)(110%)
Net Margin(626%)(20%)(626%)
FCF Margin(142%)(68%)(142%)

InSilico Medicine Cayman Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth68%(34%)
Gross Profit Growth101%(41%)
EBITDA Growth(95%)3116%
EBIT Growth(63%)86%
Net Profit Growth(92%)1961%
FCF Growth79%37%

Data powered by FactSet, Inc. and Morningstar, Inc.

InSilico Medicine Cayman Operational KPIs

InSilico Medicine Cayman's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for InSilico Medicine Cayman
Last FY202320242025202620272028
Revenue per Employee$0.2M---
Opex per Employee$0.3M---
S&M Expenses to Revenue3%2%0%3%
G&A Expenses to Revenue12%10%10%12%
R&D Expenses to Revenue145%190%107%145%
Opex to Revenue192%251%129%192%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Digital TherapeuticsHorizontal MarketplacesInvestment BankingERP SoftwareDeveloper ToolsConsumer SaaSStreamingVertical SaaSNetworking HardwareFinancial Data & InformationEnergy StorageRoad InfrastructureSemiconductors
Explore Valuation Multiples by Industry

InSilico Medicine Cayman Competitors

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E

This data is available for Pro users. Sign up to see all InSilico Medicine Cayman competitors and their valuation data.

Start Free Trial

InSilico Medicine Cayman VC Funding History

Before going public, InSilico Medicine Cayman raised $524M in total equity funding, across 10 rounds.

Last private valuation of InSilico Medicine Cayman was $1B, after raising $123M in March 2025 from Shanghai Pudong, Wuxi Capital, Prosperity7 Ventures, and 8 other investors.

InSilico Medicine Cayman Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Mar-25Series EShanghai Pudong; Wuxi Capital; Prosperity7 Ventures; Dahong Touzi; Grand Leader; Yixing Guangkong; Eli Lilly; Warburg Pincus; Pudong Chuangtou; OrbiMed; Value Partners Group$123M$1B-
Aug-22Series DBold Capital Partners; Prosperity7 Ventures; Qiming Venture Partners; Warburg Pincus; B Capital; Alex Zhavoronkov; Wilson Sonsini Goodrich & Rosati; BHR Partners; Pavilion Capital; Deerfield$35M$835MInSilico Medicine, a clinical-stage AI-driven drug discovery company, completed a second closing of its Series D funding round on August 10, 2022, raising an additional $35 million led by Prosperity7 Ventures, the venture arm of Aramco Ventures, bringing the total Series D to $95 million. Participating investors included B Capital Group, Warburg Pincus, BHR Partners, Qiming Venture Partners, Deerfield, Pavilion Capital, BOLD Capital Partners, and WS Investment Company (Wilson Sonsini Goodrich & Rosati affiliate), with founder and CEO Alex Zhavoronkov also investing. The funds aim to expand Insilico's Pharma.AI platform beyond drug R&D into sustainable chemistry, green energy, and agriculture, leveraging Prosperity7's network and Aramco's expertise in energy R&D. This builds on prior collaborations like with Syngenta in sustainable agriculture, validating the platform's multiparameter optimization capabilities. The investment diversifies Insilico's global investor base and supports Saudi Arabia's Vision 2030 tech initiatives, with potential Aramco collaborations in clean energy and environmentally friendly chemistry. Insilico highlighted recent milestones, such as nominating a preclinical candidate for its QPCTL cancer immunotherapy program in under 40 days via collaboration with Fosun Pharma. Business development remains key to unlocking Pharma.AI value.
Jun-22Series DBold Capital Partners; Qiming Venture Partners; Warburg Pincus; B Capital; Alex Zhavoronkov; BHR Partners; Pavilion Capital; Deerfield$60M$860MInSilico Medicine, operating through InSilico Medicine Cayman, is a clinical-stage AI-driven drug discovery company using generative AI platforms like Pharma.AI, PandaOmics, and Chemistry42 to identify novel targets and design molecules for diseases including cancer, fibrosis, immunology, CNS disorders, and aging. The company completed a $60 million Series D funding round on June 6, 2022, with participation from existing investors Warburg Pincus, B Capital, Qiming Venture Partners, BOLD Capital Partners, Pavilion Capital, founder Alex Zhavoronkov, and new investors including BHR Partners and a US West Coast asset manager, following a prior $255 million Series C. Proceeds from the Series D were allocated to advance its pipeline, including Phase I clinical trials for its first AI-discovered asset ISM001-055 (Rentosertib), a TNIK inhibitor for idiopathic pulmonary fibrosis, which completed a Phase 0 microdose study; seven preclinical candidates reaching IND-enabling stages; and additional programs like a COVID-19 3CL protease inhibitor and oncology targets MAT2A and USP1. The funding also supported global expansion, strategic initiatives, a robotic drug discovery laboratory, and a robotic biological data factory. At the time, Insilico had over 200 employees across six countries and was not yet profitable, focusing on R&D collaborations. The company generates revenue through R&D partnerships, including upfront payments, milestones, and subscriptions to its AI platforms, with nine of the top 20 pharma companies as licensees by 2022. Key deals included a January 2022 multi-asset partnership with Fosun Pharma, recognizing US$17.1 million in revenue that year, and a March 2022 co-development with EQRx. Overall, it has generated more than 20 clinical or IND-enabling assets, with three out-licensed for over US$2.0 billion in total contract value.
Jun-21Series CWarburg Pincus$255M-InSilico Medicine Cayman, an AI-driven drug discovery company headquartered in Hong Kong, closed a $255 million Series C funding round on June 22-24, 2021, led by Warburg Pincus with participation from investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China, and Sage Partners. The proceeds were allocated to advance current therapeutic programs into human clinical trials, initiate new programs for novel targets, and enhance AI and drug discovery capabilities. Warburg Pincus managing director Min Fang joined the board. The company operates two business models: offering AI-powered drug discovery services and software via its Pharma.AI platform, and developing its own preclinical pipeline. It has partnerships with pharmaceutical firms like Pfizer, Astellas, Johnson & Johnson, Taisho, and an exclusive deal with Syngenta for agriculture applications. Insilico Medicine, founded in 2014, had raised over $310 million total by that point, published over 130 peer-reviewed papers, and filed over 30 patents. Its AI technologies focus on target identification, molecule generation, synthetic biology data, and clinical trial predictions, demonstrating capabilities like nominating preclinical candidates in under 18 months.
Sep-19Series BBold Capital Partners; Formic Ventures; Harmonix Fund; Longevity Vision Fund; Qiming Venture Partners; F-Prime; Baidu Ventures; Sinovation Ventures; Lilly Asia Ventures; Eight Roads Ventures; Pavilion Capital$37M-InSilico Medicine, specifically referencing InSilico Medicine Cayman entities, completed a $37 million Series B funding round on September 10, 2019, led by Qiming Venture Partners with participation from Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners, and other Series A investors. The funds were allocated to commercialize validated generative chemistry and target identification technologies, build a senior management team with pharmaceutical experience, and advance its pipeline in cancer, fibrosis, NASH, immunology, and CNS for partnerships with pharmaceutical companies. The company had developed a comprehensive AI-driven drug discovery pipeline, including a molecular generator using proprietary generative and reinforcement learning technologies, and identified promising targets across multiple therapeutic areas. Insilico Medicine operated through a network of joint ventures and partnerships with early-stage biotech and large pharma companies, powering digital-age biopharma. By 2019, it had published or co-published over 70 papers in peer-reviewed journals and AI conferences, including a Nature Biotechnology paper demonstrating animal validation of novel molecules generated via deep generative tensorial reinforcement learning. Qiming Venture Partners highlighted Insilico as an industry leader in AI-powered drug discovery, anticipating shortened drug discovery timelines and synergies with portfolio companies. Later developments included a 2021 Series C raise of $255 million led by Warburg Pincus, bringing total funding over $310 million, and a Hong Kong IPO where Qiming held about 7% pre-IPO. InSilico Medicine Cayman TopCo served as the parent entity controlling subsidiaries like InSilico Medicine Cayman SubCo and Insilico Medicine IP Limited, involved in drug discovery via AI technologies.
Jun-18Series ABold Capital Partners; Wuxi AppTec; Juvenescence; Pavilion Capital$6M-InSilico Medicine Cayman is an AI-driven drug discovery company specializing in target identification, drug discovery, and aging research, based in Baltimore at the time. WuXi AppTec’s Corporate Venture Fund led a financing round around June 2018, conditional on experimental validation of Insilico’s GAN and RL-based drug discovery pipeline. WuXi AppTec planned to integrate Insilico’s AI technology into its CRO drug discovery offerings. Investors included Bold Capital Partners, Juvenescence, Pavilion Capital, and Wuxi AppTec as lead.
Jul-17Series A-$4M-InSilico Medicine Cayman raised $4 million in a Series A funding round in July 2017 to expand research and development capabilities. A prior Series A round of $2.8 million occurred in February 2017 to kickstart its AI-driven drug discovery platform. Lead investors for both early rounds were not publicly disclosed. The company develops AI-powered drug discovery platforms and therapeutic pipelines targeting diseases like idiopathic pulmonary fibrosis. Subsequent rounds included a $37 million Series B in September 2019 led by Qiming Venture Partners, $255 million Series C in June 2021 led by Warburg Pincus, and later financings up to Series E in 2025. Total funding raised across all rounds reached $609.8 million.
Feb-17Series AJim Mellon; A-Level Capital$3M-InSilico Medicine Cayman is an AI-driven biotechnology company focused on drug discovery, biomarker development, and aging research using deep learning techniques. In 2017, it received investment from billionaire Jim Mellon to validate lead molecules from its drug discovery pipelines and advance deep learned biomarkers for aging and disease. The company collaborates with pharmaceutical, cosmetics, and nutrition firms and academic institutions. In March 2017, InSilico Medicine launched its first geroprotector product with partner Life Extension. Jim Mellon, a director, brought expertise in biogerontology and networks in biotechnology and pharmaceuticals. The investment supported pre-clinical work and commercialization efforts in longevity science. Later developments include a 2019 equity raise of $36.8 million by InSilico Medicine Cayman TopCo, where James Mellon served as a director alongside others.
Nov-14SeedDeep Knowledge Group$1M--
Apr-14SeedDeep Knowledge Group; Garri Zmudze$300K--

Investments by InSilico Medicine Cayman

InSilico Medicine Cayman has invested in 1 company to date.

Latest investment by InSilico Medicine Cayman was on July 21st 2026. InSilico Medicine Cayman invested in Yuanma Intelligent Pharmaceuticals in their Seed round.

See VC round multiples

Latest Investments by InSilico Medicine Cayman

Yuanma Intelligent Pharmaceuticals
Description
Yuanma Intelligent Pharmaceuticals is a Shanghai-based biopharmaceutical company developing circular mRNA technologies for in vivo CAR-T cell therapies targeting solid tumors and hematologic malignancies. Operating via its Byterna platform, it advances cmRNA delivery systems to improve efficacy over traditional mRNA, with preclinical data presented at international oncology conferences.
HQ CountryChina
HQ City
Shanghai
Deal Date21 Jul 2026
RoundSeed
Raisedundisclosed
InvestorsInSilico Medicine Cayman; EFung Capital
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all InSilico Medicine Cayman investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About InSilico Medicine Cayman

When was InSilico Medicine Cayman founded?InSilico Medicine Cayman was founded in 2018.
Where is InSilico Medicine Cayman headquartered?InSilico Medicine Cayman is headquartered in Hong Kong.
How many employees does InSilico Medicine Cayman have?As of today, InSilico Medicine Cayman has over 319 employees.
Is InSilico Medicine Cayman publicly listed?Yes, InSilico Medicine Cayman is a public company listed on HKEX.
What is the stock symbol of InSilico Medicine Cayman?InSilico Medicine Cayman trades under 03696 ticker.
When did InSilico Medicine Cayman go public?InSilico Medicine Cayman went public in 2025.
Who are competitors of InSilico Medicine Cayman?InSilico Medicine Cayman main competitors include
What is the current market cap of InSilico Medicine Cayman?InSilico Medicine Cayman's current market cap is $3.6B.
What is the current revenue of InSilico Medicine Cayman?InSilico Medicine Cayman's last fiscal year revenue is $56M.
What is the current EV/Revenue multiple of InSilico Medicine Cayman?Current revenue multiple of InSilico Medicine Cayman is 55.8x.
Is InSilico Medicine Cayman profitable?No, InSilico Medicine Cayman is not profitable.
How many companies InSilico Medicine Cayman has acquired to date?InSilico Medicine Cayman hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies InSilico Medicine Cayman has invested to date?As of July 2026, InSilico Medicine Cayman has invested in 1 company.
What was the last InSilico Medicine Cayman investment?On 21st July 2026 InSilico Medicine Cayman invested in Yuanma Intelligent Pharmaceuticals, participating in a Seed round, alongside EFung Capital.
In what companies InSilico Medicine Cayman invested in?InSilico Medicine Cayman invested in Yuanma Intelligent Pharmaceuticals.

Lists including InSilico Medicine Cayman

Largest Companies in Hong Kong

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial